D Paul Harkin
Overview
Explore the profile of D Paul Harkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
4232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollis R, Meynert A, Michie C, Rye T, Churchman M, Hallas-Potts A, et al.
Clin Cancer Res
. 2022 Jun;
28(16):3546-3556.
PMID: 35696721
Purpose: High-grade serous ovarian carcinoma (HGSOC) is the most common ovarian cancer type; most patients experience disease recurrence that accumulates chemoresistance, leading to treatment failure. Genomic and transcriptomic features have...
2.
Lappin K, Barros E, Jhujh S, Irwin G, McMillan H, Liberante F, et al.
Cancer Res
. 2022 Jan;
82(5):819-830.
PMID: 35027467
Significance: The cancer-associated SF3B1K700E mutation induces DNA damage via generation of genotoxic R-loops and stalled replication forks, defective homologous recombination, and increased replication fork degradation, which can be targeted with...
3.
Parkes E, Savage K, Lioe T, Boyd C, Halliday S, Walker S, et al.
Br J Cancer
. 2021 Nov;
126(2):247-258.
PMID: 34728791
Background: The DNA-damage immune-response (DDIR) signature is an immune-driven gene expression signature retrospectively validated as predicting response to anthracycline-based therapy. This feasibility study prospectively evaluates the use of this assay...
4.
Hollis R, Churchman M, Michie C, Rye T, Knight L, McCavigan A, et al.
Cancer
. 2019 Jun;
125(16):2772-2781.
PMID: 31154673
Background: Approximately half of high-grade serous ovarian carcinomas (HGSOCs) demonstrate homologous recombination repair (HR) pathway defects, resulting in a distinct clinical phenotype comprising hypersensitivity to platinum, superior clinical outcome, and...
5.
Turkington R, Knight L, Blayney J, Secrier M, Douglas R, Parkes E, et al.
Gut
. 2019 Mar;
68(11):1918-1927.
PMID: 30852560
Objective: Current strategies to guide selection of neoadjuvant therapy in oesophageal adenocarcinoma (OAC) are inadequate. We assessed the ability of a DNA damage immune response (DDIR) assay to predict response...
6.
Campbell A, Morris M, Gallagher R, Boyd R, Carson H, Harkin D, et al.
BMJ Open
. 2018 Dec;
8(12):e023115.
PMID: 30580266
Introduction: BRCA1 mutation carriers have a significant lifetime risk of breast cancer, with their primary risk-reduction option being bilateral mastectomy. Preclinical work from our laboratory demonstrated that in BRCA1-deficient breast...
7.
McGivern N, El-Helali A, Mullan P, McNeish I, Harkin D, Kennedy R, et al.
Oncotarget
. 2018 Feb;
9(4):4722-4736.
PMID: 29435137
SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this...
8.
Bankhead P, Fernandez J, McArt D, Boyle D, Li G, Loughrey M, et al.
Lab Invest
. 2017 Dec;
98(1):15-26.
PMID: 29251737
Digital image analysis (DIA) is becoming central to the quantitative evaluation of tissue biomarkers for discovery, diagnosis and therapeutic selection for the delivery of precision medicine. In this study, automated...
9.
Vohhodina J, Barros E, Savage A, Liberante F, Manti L, Bankhead P, et al.
Nucleic Acids Res
. 2017 Nov;
45(22):12816-12833.
PMID: 29112714
mRNA splicing and export plays a key role in the regulation of gene expression, with recent evidence suggesting an additional layer of regulation of gene expression and cellular function through...
10.
Walker S, Knight L, McCavigan A, Logan G, Berge V, Sherif A, et al.
Eur Urol
. 2017 Apr;
72(4):509-518.
PMID: 28408174
Background: Approximately 4-25% of patients with early prostate cancer develop disease recurrence following radical prostatectomy. Objective: To identify a molecular subgroup of prostate cancers with metastatic potential at presentation resulting...